Opendata, web and dolomites

RetinDR SIGNED

RetinDR: The first topical ophthalmic formulation (eye drops) that effectively prevents and/or treats the retinal neurodegeneration induced by diabetes (diabetic retinopathy) and/or aging

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RetinDR project word cloud

Explore the words cloud of the RetinDR project. It provides you a very rough idea of what is the project "RetinDR" about.

feasibility    aged    drops       irr    wacc    adults    ophthalmic    diabetic    disease    limited    mix    progresses    business    98    peripheral    15    accounted    months    strategic    diabetes    successful    europeans    treatment    retinal    share    markets    quite    market    drug    dr    revenues    21m    licensing    arterial    industrial    double       floaters    vision    indicated    blindness    repurposing    endothelin    parent    topical    seeing    model    million    pharmaceutical    prevents    outside    receptor    commercialization       formulation    antagonist    treatments    sme    forecast    people    npv    jobs    blurred    93    prevention    2025    suffer    spots    81b    till    ebitda    difficulty    neurodegeneration    global    grow    aggressive    estimate    commercialisation    considering    equalling    completion    co    agreements    22    usually    reading    sales    52m    retinopathy    55m    retindr    worldwide    eye    stages    medical    cagr    aging    pulmonary    symptoms    2016    hypertension    treats    final    effectiveness    115    royalties    bosentan    receive    company    substance    plan   

Project "RetinDR" data sheet

The following table provides information about the project.

Coordinator
RETINSET SL 

Organization address
address: AMPOSTA 20
city: SANT CUGAT DEL VALLES
postcode: 8174
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2020-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RETINSET SL ES (SANT CUGAT DEL VALLES) coordinator 50˙000.00

Map

 Project objective

Diabetic retinopathy (DR) is the leading cause of blindness among working-aged adults. About 93 million people worldwide and 3%-4.1% of Europeans suffer this disease. The early stages of DR usually have no symptoms, however when the disease progresses it affects vision: blurred vision, seeing double, difficulty reading, spots or floaters in the field of vision, and loss of peripheral vision. Current treatments are quite aggressive, are only indicated in advanced stages of the disease, have significant side effects and their effectiveness is limited. RetinDR is a topical ophthalmic formulation (eye drops) that effectively prevents and/or treats the retinal neurodegeneration induced by diabetes (diabetic retinopathy) and/or aging. The pharmaceutical development of RetinDR is based on the repurposing of the drug substance bosentan (endothelin receptor antagonist, currently indicated for the pulmonary arterial hypertension treatment) for the prevention and treatment of DR.

The global DR market accounted for $5.81B in 2016 and is forecast to grow at 6.3%. CAGR till 2025. We estimate a market share of 0.115% 5 years after commercialisation, equalling revenues of 52M€. Our main business model will focus on sales and distribution of RetinDR in Europe through a distribution agreement with the parent company Medical Mix S.L. and co-development or licensing agreements with strategic industrial partners in markets outside of Europe where we will receive royalties.

With this model and the successful completion of the SME Phase 1 and 2 we estimate an EBITDA of over 55M€ in 5 years after commercialization an IRR of 98% and NPV of over 21M€ considering a WACC of 15%, creating 22 new jobs by 2025. The Feasibility Study for this project will take 6 months and focus on an in-depth market study, technical testing and the development of final business plan to take us to market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RETINDR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RETINDR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

IMPACT (2019)

Improving DNA Analysis for Correct Healthcare

Read More  

ARON (2020)

Assay-Ready Organ Network

Read More  

Nocturne (2019)

The eye as a window to the brain, extending lifelong brain health

Read More